You are here
The Society for Cardiovascular Angiography and Interventions (SCAI) held its annual meeting May 6-9 in San Diego. Here are some highlights from the late-breaking clinical trials.
The Heart Rhythm Society focused on the latest developments in electrophysiology and the management of patients with rhythm disorders and heart failure at its 2015 meeting on May 13-16 in Boston. The event included 12 late-breaking clinical trials.
The American College of Cardiology (ACC) held its annual conference March 14-16 in San Diego. Here are some highlights and perspectives on the sessions.
The American Stroke Association’s 2015 International Stroke Conference held Feb. 11-13 in Nashville, Tenn., likely lifted many spirits with findings that supported new therapies and identified opportunities to improve patient care.
The American Heart Association’s annual scientific session in Chicago offered insights on the latest therapies and practices, from statin treatments and screening tools to readmissions and communications.
The 2014 Transcatheter Cardiovascular Therapeutics conference held Sept. 13-15 in Washington, D.C., focused on the cutting edge in its late-breaking clinical trials and presentations. Here is a sampling.
InspireMD has received CE Mark approval for its self-expanding Nitinol carotid embolic protection stent (EPS), which is based on the MicroNet mesh protection platform technology used to treat heart attack patients with InspireMD’s coronary EPS stents, MGuard and MGuard Prime.
SAN FRANCISCO—The ORBIT AF registry, presented last week at the American College of Cardiology (ACC) annual scientific session, examined the quality of care, symptoms and one-year clinical outcomes for women vs. men with atrial fibrillation.
The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and precancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on exam of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes.
SAN FRANCISCO—Serial measurements of cardiac troponin using an investigational high-sensitivity assay enhanced risk stratification for cardiovascular disease and heart failure in patients with stable ischemic heart disease, according to an analysis of the PROVE IT-TIMI 22 study, presented March 9 at the American College of Cardiology’s (ACC) scientific session.